Received Apr 24, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| DTPPVHBHPB | DTAP+IPV+HIB+HEPB (VAXELIS) | MSP VACCINE COMPANY | UNK | — | — |
| HIBV | HIB (PEDVAXHIB) | MERCK & CO. INC. | UNK | — | — |
here were no symptomatic events from the patient. No additional AE; a patient was co-administered VAXELIS and PEDVAXHIB. Both products contain the Haemophilus b Conjugate in the vaccines; This spontaneous report was received from Other health professional and refers to a 2-month-old patient of unknown gender. The patient's medical history, concurrent conditions, concomitant therapies, past drug reactions and allergies were not reported. On 21-APR-2025, the patient was co-vaccinated with Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) (LIQUID PEDVAX HIB), Injection 0.5 mL and with Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed, Inactivated Poliovirus, Haemophilus b Conjugate [Meningococcal Protein Conjugate] and Hepatitis B [Recombinant] Vaccine (VAXELIS), Injection 0.5 mL; both administered as prophylaxis (route of administration, anatomical site of injection, vaccination scheme frequency, lot number and expiration date were not reported for any of the administered vaccines). Both products contain the Haemophilus b Conjugate in the vaccines (Overdose). There were no symptomatic events, and no additional adverse event was reported for the patient.